The COVID-19 monoclonal antibody cocktail that President Donald Trump received as treatment in the hospital is available in limited supply, so the doses must be doled out to coronavirus patients who need it the most, the drugmaker’s CEO said Sunday.Trump called Regeneron’s treatment a “cure” this week and vowed to distribute it to Americans for free. However, the company only has enough doses to treat 50,000 patients at the moment.
“We have to figure out ways to ration this,” Leonard Schleifer, co-founder and CEO of Regeneron, said on the CBS News show “Face the Nation.”
In July, the federal government signed a $450 million contract with Regeneron to create 300,000 doses. Those will be made available for free in upcoming months.
Go to WebMD to read the full story.